Search results
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and...
Digital Journal· 7 hours ago...1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy...
Jasper Therapeutics targets asthma in new Phase 1b/2a study By Investing.com
Investing.com· 2 days agoJasper Therapeutics, Inc. (NASDAQ:JSPR), a biotech company specializing in antibody therapies,...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 9 hours agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN ...
Bolt Bio halves workforce and swaps out CEO, while Tenaya lays off 5th of staff
FierceBiotech· 9 hours agoIn another tough day for biotech employees, Bolt Biotherapeutics and Tenaya Therapeutics both...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 1 day ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking ...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
FOX 59 Indianapolis· 7 days agoEupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a...
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 14 hours agoQ: What insights have been gained regarding the lack of ARIA-E observed in APOE4 homozygotes and its occurrence only in females from the Phase 1b study? ...
Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears
FierceBiotech· 2 days agoAC Immune is currently evaluating ACI-24.06 in a phase 1b/2 trial in subjects with prodromal...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
Fontana Herald News· 2 days agoGLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days ago-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment ...